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Data-driven business models make up the medical and healthcare market in large parts, a 
trend reinforced by further technological developments and regulation. Care must be taken 
to avoid a situation where only a few players benefit. It’s weird the patient has to become a 
customer in order to be a human being in the health business: The consistent empowerment 
of patients to handle their own data is essential. 
	
		
1  Most parts of this article have already been published in HealthManagement.org 2018, Volume 18, Issue 6, p. 
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I. THE DIGITAL DATA WORLD IS BECOMING THE CORE OF MEDICINE 
AND HEALTHCARE 
 
Who lives outside the GAMFANNAT economy (Google2, Apple3, Microsoft4, Face-
book5, Amazon6, Netflix7, Alibaba8, Tencent9)? An increasing market capitalization of 
approximately $5 trillion (July 2018) – a multiple of the market value of all German DAX 
30 companies together – and an even deeper connection of services and products with our 
increasingly digitally organized and experienced life clearly show that large parts of the 
global consumer society today and even more tomorrow and the day after tomorrow will 
become data-driven spheres. It is easy to imagine a world without fossil fuel-powered au-
tomobiles – but with flying autonomous vehicles, a bit harder without cell phones - and 
with brain implants - but a world without data in the sense of their intensive generation 
and usage, and practically in all areas of life – it seems to be hardly tangible (unless as a 
conscious and fairly complete renunciation of technology).  
 
The development of data-driven activities as a whole is increasingly ethically questioned. 
In Germany, the Data Ethics Commission10 has recently been created within the Federal 
Ministry of Interior, Building and Community, and in England the Data Ethics Frame-
work11 of the Department for Digital, Culture, Media and Sport. Today, it is equally un-
	
		
2  For insights into strategies and business cases for listed companies, investor relation platforms are helpful 
(alongside with (good) capital market research); Alphabet Investor Relations, https://abc.xyz/investor/ (last 
visited Oct. 20, 2018, 09:21 AM). 
3  Apple Investor Relations, https://investor.apple.com/investor-relations/default.aspx (last visited Oct. 20, 
2018, 09:11 AM). 
4  Microsoft Investor Relations, https://www.microsoft.com/en-us/investor (last visited Oct. 20, 2018, 09:10 
AM). 
5  Facebook Investor Relations, https://investor.fb.com/home/default.aspx (last visited Oct. 20, 2018, 09:04 
AM). 
6  Amazon Investor Relations, https://ir.aboutamazon.com/ (last visited Oct. 20, 2018, 09:16 AM). 
7  Netflix Investors, https://ir.netflix.com/ir-overview/profile/default.aspx (last visited Oct. 20, 2018, 09:23 
AM). 
8  Alibaba Group, https://www.alibabagroup.com/en/ir/home (last visited Oct. 20, 2018, 09:25 AM). 
9  Tencent Corporate Governance, http://www.tencent.com/en-us/investor.html (last visited Oct. 20, 2018, 
09:31 AM). 
10  Datenethikkommission, Bundesministerium des Innern, für Bau und Heimat (Data Ethics Commission, Fed-
eral Ministry of the Interior, for Building and Community) https://www.bmi.bund.de/DE/themen/it-und-
digitalpolitik/datenethikkommission/datenethikkommission-node.html (last visited Oct. 20, 2018, 09:37 
AM). 
11  Guidance – Data Ethics Framework, Department for Digital, Culture, Media & Sport (updated Aug. 30, 2018), 
https://www.gov.uk/government/publications/data-ethics-framework/data-ethics-framework (last visited 




COMPLIANCE  ELLIANCE  JOURNAL   |    VOLUME 4   NUMBER 2   2018 
STEFAN HEINEMANN   |   DATA POWER TO THE PATIENTS!  
PATIENT-DRIVEN DATA BUSINESS, NOT DATA-DRIVEN PATIENT BUSINESS 
 
PAGE  54 
imaginable not using the digital advances in medicine – which are certainly critical in eth-
ical terms, yet impressive, especially the data-driven ones – for positive precaution, diag-
nosis, healing and aftercare opportunities for patients and healthy people. From AI in 
radiology to precision medicine in oncology, people want to be, become, and stay healthy. 
Here a peculiar tension erupts. 
 
In the GAMFANNAT world, considerably more people are using the services offered 
than would be expected in view of the level of trust that users have in their data usage – 
apart from the fact that hardly anyone, for example, really works through, understands or 
can decipher privacy statements. Transparency as a condition of the opportunity for fair 
consent looks different. To put it clearly: The GAMFANNAT Grandpa should not be 
sitting next to Lehman Granny. Nor is it to be expected that, in the end, patients will not 
give priority to the medical benefit of their data because of concerns about a "patient 
credit bureau" – even if the treatment contexts are hardly accessible to the individual pa-
tient. Convenience has always limited data protection requirements in real terms, and data 
protection should not be a luxury for the healthy. In addition, the GAMFANNAT play-
ers are already today – recognizable openly or only in contours – increasingly active in the 
medical and healthcare market and game changers.12 
 
So what data-related opportunities and risks arise for patients from a business perspec-
tive? How can patients not only be masters of their data, but use data business cases for 
themselves? What is the value of their medical and health-related data? Which commer-
cial, social or individual medical use of personal data makes sense and is as safe as it can be 
safe in the digital realm? 
II. ECONOMICALLY, DATA IS NEITHER OIL NOR CURRENCY – BUT NEV-
ERTHELESS THE CENTRAL FUTURE EXCHANGE UNIT FOR PATIENTS 
 
Economically, oil is private property with exclusive ownership. My oil is my oil and only 
I can use it, nobody else. And when it's used up, it's gone. And I can only use one liter of 
	
		
12  Google: Recently expansion into healthcare, strong strategic focus (Google in Health, GOOGLE 
https://www.google.com/intl/en_us/health/about/ (last visited Oct. 20, 2018, 10:01 AM)); Apple: Recently 
Apple Watch 4 has been classified as an FDA class 2 medical device and launched the project of medical clinics 
for employees, strong strategic focus (Healthcare- The future of healthcare is in your hands, APPLE, 
https://www.apple.com/healthcare/ (last visited Oct. 20, 2018, 10:12 AM)); Microsoft: Recently more azure 
services for next gen medical data (e.g. Genomics), strong strategic focus (Health - Learn more about what 
Microsoft is doing in Health, MICROSOFT, https://www.microsoft.com/en-us/enterprise/health (last visited 
Oct. 20, 2018); Facebook: Recently data sharing agreement with hospitals, growing strategic focus (Christina 
Farr, Facebook sent a doctor on a secret mission to ask hospitals to share patient data, CNBC (Apr. 5, 2018) 
https://www.cnbc.com/2018/04/05/facebook-building-8-explored-data-sharing-agreement-with-hospi-
tals.html (last visited Oct. 20, 2018, 10:17 AM)); Amazon: Recently partnering with JPMorgan Chase and Berk-
shire Hathaway, yet unclear goal, probably using the sales and payment power of Amazon for healthcare, phar-
macy or insurance to increase efficiency in healthcare (Zachary Tracer, Amazon-Berkshire-JPMorgan Health 
Venture Takes Aim at Middlemen, BLOOMBERG (Jun. 24, 2018) https://www.bloomberg.com/news/arti-
cles/2018-06-24/amazon-berkshire-jpmorgan-health-venture-takes-aim-at-middlemen (last visited Oct. 20, 
2018, 10:22 AM)); also Netflix, Alibaba, Tencent are active, also Uber et al. 
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oil to the extent of one liter of oil. If I mix 1,000 liters of oil, it won’t become "super oil". 
In economic terms, data have a completely different nature. I can share my data with mul-
tiple users, so they are not rivals, and when many different pieces of data come together, 
they create network effects that can in part lead to significant benefit increases. In addi-
tion, data can be copied virtually unlimitedly, does not wear out, can be transferred, and 
can be handled through access, use, and change, and distinguished into private club goods 
or public data assets (e.g. weather data). And you can do amazing mathematics with it: 
statistics is the new basic subject for understanding the data economy.  
 
My personalized medical data may only have limited economic value for me – which may 
be existential – but economically cannot be increased arbitrarily. However, for a com-
pany, various data such as my personalized but also impersonalized data (anonymized, 
pseudonymized, or purely machine-generated) can, when aggregated, lead to completely 
new insights and offers, and in the end even to innovative value added – especially in 
modern data medicine, such effects are currently on the agenda, and therefore, for exam-
ple, for the pharmaceutical industry, of great interest.  
 
The emancipation of correlation versus causality does not take place in strict scientific 
theory, but in the pragmatic world of business models13 – even with seriously anonymized 
data, cross-referencing and correspondingly smart data analysis models can often at least 
compensate for the information about the person that has been legally deleted, provided 
that those data are cleverly combined with other data (e.g. data from search engines or 
fitness devices) apart from that it is known that 87 percent of the US population can be 
re-identified by the combination of zip code, gender and date of birth.14 Precisely because 
my data does not generally represent a significant value for me, there was – and is – a 
tendency to pass it quite relaxed to the companies in exchange for services and products. 
That's just how it is as a consumer: “If you are not paying for it, you're not the customer; 
you're the product being sold”.15 
 
In the end, to a large extent, the enormous market value of the corresponding data-driven 
companies is explained. Because they do not really share the cake. With a view to patients, 
this trend slowly begins to gain contours in the medical and healthcare sector. Strictly 
speaking, the medical data of patients is not a currency for patients themselves, because 
they are not a constant reference value, but depend essentially on their context. However, 
	
		
13  To be very clear here: „In today’s world, there is a growing tendency to trust personal beliefs, superstitions, 
and pseudoscience more than scientific evidence.“, Helena Matute, Fernando Blanco, Ion Yarritu, Marcos 
Diaz-Lago, Miguel A. Vadillo & Itxaso Barberia, Illusions of Causality: How They Bias Our Everyday Think-
ing and How They Could be Reduced, 6 FRONTIERS IN PSYCHOLOGY, 888 (2015) – That is an unacceptable 
tendency. We should not let Bias become acceptable. It might be true, that rich people have big feet – if I hit 
the jackpot my feet will not grow - but that does not excuse to hit the other extreme: Of course correlation-
based business models can make sense and produce value for customers. 
14  Latanya Sweeney, k-anonymity: a model for protecting privacy, 10(5) INTERNATIONAL JOURNAL ON UNCER-
TAINTY, FUZZINESS AND KNOWLEDGE-BASED SYSTEMS, 557-570 (2002). 
15  Andrew Lewis via Twitter, Sept. 13, 2010, available at: https://twitter.com/andlewis?lang=en (last visited Aug. 
10, 2018, 03:25 PM). 
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data can replace financial transactions via their specific value – and yet, no oil, no cur-
rency, but an economic value that should be repaid. 
III. BUSINESS MODELS FOR THE USE OF MEDICAL DATA AND IDEAS FOR 
DETERMINING THE VALUE OF DATA ARE DIVERSE AND RARELY REC-
OGNIZABLE TODAY 
 
Which business models in the medical and healthcare industry use data and how is this 
money earned? This very simple-sounding question says it all. In principle, data can be 
traded or used directly (or as in the case of open-data provided without consideration, or 
data sharing). The GAMFANNAT economy usually does the latter and thus comes to 
steadily richer and deeper user experiences and increased, individual benefit, leading to a 
corresponding willingness to pay and, above all, loyalty – and last but not least, to com-
petitive advantages. The algorithms of the companies are ultimately unregulated and in 
large parts even for an insider a black box – which makes the exact analysis of the value-
added context not easier, as well as a social assessment (think of the potential for discrim-
ination, currently the Berlin initiative d2116 is taking corresponding first steps with the ex-
pert group "Algorithms Monitoring"). What is still emerging in medicine as personalized 
medicine, for example, is for consumers of media an everyday experience (certainly media 
are far less complex and consequential). Today we see no “MediFy”, but Spotify 17 
 
When it comes to trading data (as practiced by IQVIA18, for example), transparency is less 
visible. Who really knows how their health insurance provider does the ultimately decisive 
risk assessment? Which data were used? The fact that you can no longer digitally live with-
out advertising and this advertising is personalized on a data-driven basis, may cost some 
nerves and evoke countermeasures, such as paying for less advertising; others enjoy hyper-
personalized content – but ultimately, it's a comparatively less critical data usage. With 
Patient Data Selling you will want to look more closely – and have to. The opt-out must 
always be possible for the patient, but today it is not. Just say “No” if you do not want to 
be part of the game (as long as it is doable for the average person). And a solution such as 
privacy-enhancing tools, which are available for online offers, for example, are far from 
available for medical data and records. The data system of the medical and health industry 
has a breathtaking opacity. 
 
Good providers of data services will ensure transparency and participation, and legally 
	
		
16  See: Netzwerk für die Digitale Gesellschaft (Network for the Digital Society), D21 https://initiatived21.de/ 
(last visited Oct. 20, 2018, 01:01 PM). 
17  Spotify is partnering with DTC-Company Ancestry to combine playlists with DNA (If you could listen to your 
DNA, what would it sound like?, ANCESTRY, https://www.ancestry.com/cs/spotify (last visited Oct. 20, 2018, 
01:15 PM) – sounds wired but entertainment is a valid way to create awareness and to start the empowerment, 
just think of gamefication as a means to create smart learning effects. 





COMPLIANCE  ELLIANCE  JOURNAL   |    VOLUME 4   NUMBER 2   2018 
STEFAN HEINEMANN   |   DATA POWER TO THE PATIENTS!  
PATIENT-DRIVEN DATA BUSINESS, NOT DATA-DRIVEN PATIENT BUSINESS 
 
PAGE  57 
offered to patients integrating them economically (and of course the doctors, who will 
soon be seeing new business models in the house, new risks but also new opportunities; 
no AI will ever replace a good heart (until we do not see an AI as an Existence in the full 
ethical sense) and doctors are always the natural intelligence needed, think of the actual 
critical discussion of Watson19 (IBM)). And pay attention to the data quality: Statistical 
modeling is only suitable for intervention in medicine, if it has at least objectivity, relia-
bility and validity with regard to the actual data used and the corresponding analysis 
methods. With good data, medical systems can be trained and multiple variables can clev-
erly be linked to newly empirically demonstrable correlations, which in turn may suggest 
prevention or therapy. Unfortunately, even with data success, neither the corresponding 
model can be verified nor a causality be proven. Statistics make more or less meaningful 
predictions depending on the sample size. But that's just what makes new hypotheses pos-
sible. And with the exponentially growing flood of information in the medical sector, it's 
difficult to avoid big data and AI (& Co.). In this sense, in my opinion, patients in the 
medical and healthcare sector want to deal with their data more sensitively than in previ-
ously common consumer areas – and hopefully do it well-informed – and in the end want 
to use the statistically usable or even personal data generated value. 
 
On the other hand, what speaks in principal against patients paying in a transparent and 
well-structured manner, for example, special medical services in a smart hospital with their 
data? Self-pay may also be achievable for less wealthy patients. What speaks against a pa-
tient selling or licensing their genetic data for legal and legitimate and transparent pur-
poses? In the upcoming DNA marketplace, the DNA “donors” should get an economic 
participation and become “business partners”; smaller companies such as EncrypGen20 or 
Nebula Genomics21 look for appropriate solutions, and often-key technologies such as 
Blockchain play a crucial role. Consequently, questions about the taxation of data will 
also have to play a bigger role in the future. And, of course, security and economic value 
issues – hacker attacks from outside and criminal energy within medical institutions – are 
likely to increase as the incentive potentially increases. 
 
Patients may not have a clear understanding of what their data is really worth, and most 
of them might not care about the business models at this stage without recognizable par-
ticipation (in a democratic sense). Companies in the medical and healthcare industry have 
a decisive advantage here, not least because the value of data constantly changes with the 
context of (today often unclear, but tomorrow…) business models. Of course, companies 
are often denied the final clarity on digital business models in the smart healthcare world. 
In the end, it will be crucial whether patients are adequately involved in certainly-not- 
	
		
19  Annie Palmer, IBM's Watson AI suggested 'often inaccurate' and 'unsafe' treatment recommendations for can-
cer patients, internal documents show, DAILY MAIL ONLINE, https://www.dailymail.co.uk/sciencetech/arti-
cle-6001141/IBMs-Watson-suggested-inaccurate-unsafe-treatment-recommendations-cancer-patients.html 
(last visited Oct. 20, 2018, 01:28 PM). 
20  EncrypGen, https://encrypgen.com/ (last visited Oct. 20, 2018, 01:33 PM). 
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marginal welfare gains. Enlightenment is likely to be necessary not only in legal but also 
in economic terms, otherwise consent declarations remain notoriously ineffective and 
economically not necessarily positive for the client or patient, because the data-collecting 
company determines what data it collects for what. But alternatives are also discussed, for 
instance, personal information management systems (PIMS22). Also important are Smart 
Communities to engage Patients in Dialogues about their data commercialization enter-
prise among themselves and with medical and other experts.  
 
Not least so that the patients not only – as usual in the data economy from the customer's 
point of view – look for short-term benefits such as discounts or the like, but also take 
long-term positive effects into focus. This decision-making need not necessarily leads to 
the decision between added value and the protection of data but can combine both ele-
ments. It will not necessarily be about life-changing business when patients use their data 
or parts of their data economically. But then they are in the game, sitting at the table, and 
they also should sit there, if, in the end, it comes not through advertising but e.g. via in-
surance model-funded data platforms. At the end of the day, the patients themselves can 
increase the price and promote transparency by treating their data with the utmost care, 
which will be essential for an adequate position of providers (patients) towards buyers 
(companies). And today it is not foreseeable whether there will be minimal value added, 
exchangeable, or even a greater value added in the individual economic exploitation of 
individual, personalized or impersonalized data. A third way to do this would be to point 
out the current, ultimately unquestioning availability of data and self-marketing of the 
individual, which is likely to lead to lower prices through asymmetry. 
 
Unlike other consumer data, medical data is absolutely necessary for factual medical care, 
but for the healthy some medical data are theoretically economically usable even without 
specific treatment, and not even prevention. Finally, the entire life as a prevention and 
data event is newly articulated in the quantified self. It will probably result in a holistic 
path connecting EMR Data, wearables, and B2C-driven genetic data. A conceivable im-
pact can be the connection between pay and data exploitation, as it is known and prac-
ticed in the media industry23. The licensing of intangible assets answers the question as to 
which data, where, when, for how long, to whom and for what purpose and consideration 
are put into use.24 Companies like to talk about "data ecosystems" as Terminus Technicus 
instead of "trade". Platforms to value and trade/licence C2B and maybe even C2C could 
	
		
22  Personal Information Management System, European Data Protection Supervisor, https://edps.eu-
ropa.eu/data-protection/our-work/subjects/personal-information-management-system_en (last visited Oct. 
20, 2018, 01:37 PM). 
23  It is expectable that disruptive media businesses – e.g. in video gaming, music, film (content) and advertising 
(which see a digitalization-driven convergence tendency in their own value chains) – will cooperate with health 
data businesses (see footnote 6 for a recent example). One reason besides value creation might be located in the 
inner logic of these data-business. 
24  Wolfgang Kerber, Digital Markets, Data, and Privacy: Competition Law, Consumer Law, and Data Protec-
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be an instrument – but always and only if Patients are educated to handle their medical 
data, which is for example for sure one of the challenges von DTC (direct to consumer) 
genomic businesses (23andme25 etc.) because People are confronted with information 
(might it not be a diagnosis) which they maybe are not able to handle on their own with-
out further professional advice, e.g. by a doctor.  
In practice, such basically legal issues are not really resolved. In the case of personal data, 
the term "property" – or at least property-like entitlements – may be used, and in the case 
of non-personal data, it may be called a copyright aspect. Since there are many mergers of 
data forms that are likely to increase in the Internet of Things era, even this distinction 
with property reference may be difficult in practice, and thus the likelihood of lower 
transaction costs for personal data and its markets. The lawyers will get a lot to do. 
 
If it is ethically correct and therefore legally required in a constitutional state to focus on 
the patient's benefit, and also economically attractive – albeit a little weird that the patient 
has to become a customer in order to be a human being with dignity in the health business 
– then the consistent empowerment26 of patients to handle their own data is essential. 
And this does not in the least include the benefit that these can provide – only for the 
individual patient medically, but also financially, or, for example, by means of data dona-
tion in research, potentially for society as a whole or in cooperative models (eg Health-
bank27 in Switzerland). For this, a social consensus must be worked out that supports this 
form of economic participation. In addition, the lack of factual interoperability of exist-
ing patient records is a major obstacle for convincing implementation – and a significant 
costly one as well. There are initiatives such as MyData28 from Finland, which generally 
demand a "human-centered personal data management" for data, and with the concept of 
the "Self-Sovereign Identity Systems" the final idea of the autonomy of users finds its way 




25  23andMe, https://www.23andme.com/en-int/ (last visited Oct. 20, 2018, 01:56 PM). 
26  Approaches such as gamification might be useful here, just as the inclusion of relevant multipliers in the edu-
cational realm, e.g. schools for continuing non-credit education (so-called „Volkshochschulen“ in Germany). 
In my opinion the issue of health data has to be addressed from kindergarten to higher education and for every 
target group – think of STEM Initiatives to foster tec talents for example.  
27  Health Bank, https://www.healthbank.coop/ (last visited Oct. 20, 2018, 02:52 PM). 
28  Mydata Finland, https://mydata.org/finland/ (last visited Oct. 20, 2018, 02:21 PM). 
29  Longenesis, http://longenesis.com/ (last visited Oct. 20, 2018, 02:16 PM). 
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Figure 1: The centrality of the patient in the commerce of digital healthcare 
 
 
IV. THE GDPR POTENTIALLY DRIVES THE INDIVIDUAL DATA BUSINESS IN 
MEDICINE 
 
In my opinion, the General Data Protection Regulation (GDPR)30 tries to manage the 
balancing act between data protectionism and innovation bondage in favor of a reasona-
ble middle-of-the-range solution. It can – despite all certainly not unjustified criticism in 
detail – become the gold standard (for now) to make personal data with privacy and data 
portability a valuable asset in a seller's market. Businesses, as well as other public-sector 
institutions, for example, who deal with impersonalized data and, most importantly, per-
sonal data of patients, are highly demanded to ensure the maximum possible security of 
this data from misuse. Since like I mentioned true impersonalized data is not easy to grant, 
this form of data although not covered by the GDPR should be considered data protec-
tion relevant when we talk about patient data. 
  
Additionally, it is a good initiative of the GDPR to put the consent clearly in the center. 
It is about protection people, not protecting data.31 In the end, patients will have to learn 
	
		
30  Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection 
of natural persons with regard to the processing of personal data and on the free movement of such data, and 
repealing Directive 95/46/EC (General Data Protection Regulation), EUR-Lex, https://eur-lex.europa.eu/le-
gal-content/EN/TXT/?uri=CELEX:02016R0679-20160504 (last visited Oct. 20, 2018, 04:26 PM). 
31  The GDPR, in fact, is counterproductive when it comes down to the real business life. A little less complex, 
rigid and punitive might have been more suitable. In Germany things are, of course, even more complex. 18 
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to responsibly handle the most valuable data they have – their medical data – and to read 
the privacy policy. The "fine print" re-enters the consciousness – and that's a good thing. 
In addition, the much-cited informational self-determination is no guarantee of absolute 
power of the individual over "their" data – because also the protection of privacy takes 
place in a social context. And yet there remains the problem that the GDPR does not 
directly address the involvement of consumers in the economic exploitation of their data. 
It is easy to understand, however, that consumers want more than data protection as soon 
as the economic opportunities in data markets become clearer to them.32 At the end of the 
day, it should be similar for patients – not just because of private return perspectives but 
also to foster their healthcare outcomes. Which on the other hand might also increase 
their motivation e.g. to share their data with research organizations and become a proud 
data donor. Precision medicine for everyone needs so many institutional barriers to over-
come – Patients as smart customers can make it happen.  
 
No sensible person can object to better medicine; however, care must be taken to ensure 
that there are no distorting data monopolies and non-transparent business models that in 
the end only really benefit a few players. If a legal, legitimate and efficient business is to 
emerge, it must properly engage patients as customers and data providers in the value 
chain. The centrality of the patient in the commerce of digital healthcare is crucial – also 
from my point of view for a holistic patient experience - even though it may be very com-
plex and difficult, it is not impossible. 
	
		
way to protect people and business as well as to help to avoid the misuse of their data than the current confus-
ing legal framework. An international comparison of approaches is possible, e.g. the Hong Kong Personal Data 
(Privacy) Ordinance, the Australian Privacy Act, the Singapore Personal Data Protection Act etc. - for a good 
global overview check: Data protection around the world, DNIL, https://www.cnil.fr/en/data-protection-
around-the-world (last visited Oct. 20, 2018, 04:31 PM). 
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